A CDMO Dedicated to Supporting Small-Volume, Small-Molecule Parenteral Projects

Brochure describing Grifols Partnership services, products and capabilities offered to pharmaceutical companies. Featuring two FDA approved Manufacturing sites

Have you ever wondered what Grifols sites around the world are like? This aerial tour video provides a great visual perspective of various sites. Take two and a half minutes to watch it and see our sites around the world.

In this exclusive interview, Marga Viñes, Senior Business Development Manager for
Contract Manufacturing and Carla Mössinger, Business Development Manager for IV Solutions & Contract Manufacturing answer questions about  the quality, flexibility, and efficiency of Grifols Partnership CDMO services.

Our customers are happy customers! See what they say about our contract manufacturing services and what is like to trust their project in us!

Michael Howell, Site Director of Albumin Manufacturing at Grifols, speaks with Nigel Walker about how Grifols’ state-of-the-art facility in Dublin meets client demands in this new era in healthcare. They also discuss how risk assessment plays a major role in Grifols' success with customers.

Watch Pharma’s Almanac exclusive interview with Oriol Prat, Oriol Argemí and Marga Viñes, about trends in parenteral manufacturing, and how Grifols is maintaining its leadership in the small-volume parenteral manufacturing market.

Drug candidates are becoming increasingly complex as manufacturers continue to focus on niche and personalized medicines. Contract development and manufacturing organizations with process and capacity, flexibility, and wide-ranging expertise in small-volume GMP manufacturing are needed to support efforts by pharma companies to rapidly bring these specialized products to the market.

In the competitive pharmaceutical manufacturing landscape, the ability to continuously achieve improvements in efficiency and productivity is essential to success. Given the higher complexity of parenteral drug manufacturing, continuously improving production processes is also paramount for ensuring the highest level of quality.

Extensive process understanding is required to ensure the consistent manufacture of high-quality sterile parenteral products. At Grifols, our use of state-of-the-art automated aseptic processing systems, including form-fill-seal (FFS) technology, ensures control with minimal human intervention.

Combining the focus on parenteral with the expertise of an established pharmaceutical leader, the contract manufacturing business is agile and flexible in its service to companies outsourcing the development and manufacture of added value injectable drugs.

Grifols Partnership brochure describing our CDMO services.

Watch Neil Owens' interview, President and Chief Operations Officer at Medicure Inc about their experience working with Grifols Partnership.